Royalty Pharma plc
RPRX
Classement en actions
#868
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a... Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Prix de l'action
$62.21
Dernière synchronisation: 2026-10-20
Capitalisation boursière
$27.70B
Changement (1 jour)
3.22%
Changement (1 an)
65.98%
Pays
US
Échange Royalty Pharma plc (RPRX)
Catégorie
Healthcare
Ratio P/S pour Royalty Pharma plc (RPRX)
Ratio P/S au October 2026 TTM : 10.31
Selon les derniers rapports financiers et le cours de l'action de Royalty Pharma plc, le ratio cours/ventes actuel (TTM) est 10.31. À la fin de 2023, le ratio P/S était de 5.34.
Historique du ratio P/S pour Royalty Pharma plc de 2015 à 2026
Ratio P/S à la fin de chaque année
| Année | Ratio P/S | Changez |
|---|---|---|
| 2026 (TTM) | 10.31 | 104.99% |
| 2024 | 5.03 | -5.87% |
| 2023 | 5.34 | -30.98% |
| 2022 | 7.74 | 7.16% |
| 2021 | 7.22 | -21.12% |
| 2020 | 9.15 | 5.36% |
| 2019 | 8.69 | -1.07% |
| 2018 | 8.78 | -10.97% |
| 2017 | 9.86 | -31.45% |
| 2016 | 14.39 | -11.98% |
| 2015 | 16.35 | 0.00% |
Ratio P/S pour des entreprises similaires ou concurrentes
| Entreprise | Ratio P/S | Différence de Ratio P/S | Pays |
|---|---|---|---|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 15.12 | 46.67% |
US
|
|
| 2.36 | -77.11% |
HK
|
